Featured Employee Spotlight
Xichen Nie, PhD
Scientific Manager
Xichen holds a BS in life sciences from Sun Yat-sen University in China and a PhD in oncological sciences from the University of Utah. Her graduate work, under the mentorship of Drs. Bradley Cairns and Jingtao Guo, focused on human male reproductive biology. She specializes in single-cell genomics, germline stem cell biology, and testicular development. Currently serving as Scientific Manager at Paterna, Xichen leads a team dedicated to developing cutting-edge technologies for human in vitro spermatogenesis. In her spare time, she enjoys fitness, gardening, and spending time with her family.
Jim Hotaling, MD, MS, FECSM
Co-founder and Chief Medical Officer
Jim is a urologist, serial entrepreneur, scientist and Director of Men’s Health at the University of Utah. He received his BA from Dartmouth, his MD from Duke and his MS in clinical epidemiology from the University of Washington. Jim completed a fellowship in male infertility at The University of Illinois at Chicago and joined the faculty at University of Utah. He built the reproductive urology program at RMANJ, which was acquired by IVIRMA, the largest IVF clinic in the world. Jim has founded five companies, exited two, holds 8 patents, has over 250 publications in the men’s health and male infertility space and has served as the president of the Society for Male Reproductive Urology. He has worked with Drs Guo, Cairns, Nie and Pastuszak for over a decade and developed the idea for Paterna after having to tell many patients that they could not have biological children. In his spare time he enjoys road and mountain biking, ski mountaineering, climbing and time with his wife and two boys.
Brad Cairns, PhD
Co-founder and Chief of Scientific Advisors
Brad received his BS in Chemistry from Lewis and Clark College, his PhD in Cell Biology from Stanford University, and conducted his postdoctoral training in genetics at Harvard Medical School. He is the Chief Academic Officer at Huntsman Cancer Institute, and also Professor and Chair of the Department of Oncological Sciences – both at University of Utah School of Medicine – where he holds the Jon M. Huntsman Presidential Endowed Chair in Cancer Research. His scientific work focuses on understanding how chromatin structure and remodeling regulates gene expression, and his lab has provided multiple insights into how chromatin structure is established and remodeled to control gene expression and development in the germline and early embryos, including in the setting of spermatogenesis. Brad is an Investigator with the Howard Hughes Medical Institute (HHMI) and is a co-founder of Paterna Biosciences Inc., where he serves as Chair of Scientific Advisors. He was elected to the American Academy of Arts and Sciences in 2017 and to the Royal Society in 2023.
Alex Pastuszak, MD, PhD
Co-founder and Chief Executive Officer
Alex is an urologist, scientist, and serial entrepreneur, bringing over 15 years of experience in healthcare and biotechnology to Paterna. He received his BS from Yale University and his MD and PhD from the University of California, San Francisco. Alex completed his residency and fellowship training in urology and male reproductive medicine and surgery at Baylor College of Medicine, and started his career as an academic physician-scientist, transitioning more heavily into startups and growth companies over the last decade. Alex’s clinical and NIH-funded basic research focus as faculty at the University of Utah is in men’s sexual and reproductive health, and his entrepreneurial work has encompassed healthcare technology, diagnostics, medical devices, clinical research, and medical innovation. Alex has had founding and executive operational roles at multiple companies, with several exits to date, most recently at Vault Health, where he served as Chief Medical & Scientific Officer. In his spare time, he enjoys endurance cycling, skiing, good wine, and spending time with his wife and two boys.
Jingtao Guo, PhD
Jingtao is a professor and investigator at the Institute of Zoology, Chinese Academy of Sciences in Beijing, China. He received his BS from Peking University, and his PhD from University of Utah under the mentorship of Dr. Brad Cairns. He completed his postdoctoral training with Drs Brad Cairns and Doug Carrell, and was subsequently appointed as an Assistant Professor at the University of Utah School of Medicine. Jingtao has worked with Brad, Jim, and Xichen on human germline stem cells and testis development for a decade. In late 2021, after living in Utah for almost 10 years, Jingtao and his family moved back to Beijing, where he leads a ~20 member research group and continues his research on human reproduction and testis biology. In his spare time, he enjoys reading books, listening to music, hiking and traveling with his family.
Kyle Orwig, PhD
Kyle received his BS in Biology and BA in Chemistry from Whitworth College and his PhD in Biochemistry & Biophysics and Animal Sciences from Oregon State University. His postdoctoral training was at Kansas University Medical Center and then University of Pennsylvania where he started his life’s work on stem cells, gametogenesis and fertility. He is a Professor of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh where his lab has pioneered methods for testicular stem cell and testicular tissue transplantation to treat male infertility. He is the founding director of the UPMC Fertility Preservation Program and the UPMC Magee Center for Reproduction and Transplantation (CRT) that is committed to translating lab bench discoveries into clinical practice. CRT provides fertility preservation and fertility restoration services to patients in Western Pennsylvania and through a coordinated network of more than 40 sites around the US. His team is committed to improving access to fertility care for all people and working toward a future where every person who wants to have a biologically related child can do so.
Meredith Vadis
Chief Operating Officer
Meredith Vadis is a transformative leader with a history of building high-performing organizations. She provides fractional executive, operational, and administrative leadership to small and mid-sized companies, including Paterna Bio. Previously, Meredith was President of Vault Workforce Screening, a nationwide employment screening solutions provider, where she successfully modernized and sold the company in less than two years. During the first year of the pandemic, she created, built, and ran Minnesota’s COVID-19 statewide public testing system. Later, at Vault Health, she led the governmental COVID testing and vaccination partnerships with more than a dozen states. Meredith was also Regional Administrator (Chief Executive Officer) for one of the largest U.S. regional governing bodies, which oversees mass transit, wastewater utilities, regional economic development and urban land planning.
Meredith holds a Bachelor of Arts in English and Political Science from Marquette University and a Master’s in Public Policy from the Humphrey School of Public Affairs at the University of Minnesota. She began her career leading communications on electoral campaigns and running federal offices for a Member of Congress.
With a proven track record in both the public and private sectors, she leverages her multi-sector experience, clear communication, accountability, and collaborative leadership to help organizations minimize risk and maximize operational capacity and efficiency. Meredith turns the unknown and uncertainty into tangible action, empowering companies to achieve extraordinary outcomes.
Danny Mitchell
Danny has been building businesses for 20 years, both at top-tier investment banks and startups. Previously, he was the Chief Executive Officer at CircleUp, a consumer data analytics platform that was acquired in 2023. Prior to CircleUp, Danny was Chief Financial Officer and Head of Operations at Chargeback, a Saas FinTech company, where he led its acquisition by Sift. Further back, Danny was Chief Financial Officer and Chief Compliance Officer at Red Cedar Investment Management and a Vice President at Goldman Sachs. He received a combined Bachelor of Science and Arts in Accounting and Economics from Bucknell University. Originally from New York, Danny has lived in Salt Lake City for ten years. In his spare time, he enjoys skiing, golfing, mountain biking, and camping with his family.
Hollie Chan
Hollie Chan holds an M.B.A. in Management and Finance from Tulane University and a B.S. in Marketing and Communications from Louisiana State University. With a diverse background that spans roles such as contracts negotiator at Lockheed Martin, business owner, and executive-level support at healthcare startups, she brings a wealth of experience to her endeavors. Hollie has collaborated with executive teams to streamline communications, optimize workflows, and foster interdepartmental collaboration. Her meticulous attention to detail and exceptional organizational skills enable her to excel in roles requiring precise execution and strategic thinking.
Recognized for her adept problem-solving ability, she navigates ambiguous circumstances with ease, consistently delivering tangible results. Residing in Gulf Breeze, Florida, she enjoys tennis, beach outings, boating, and spending quality time with her husband and three boys.
Xichen Nie, PhD
Scientific Manager
Xichen holds a BS in life sciences from Sun Yat-sen University in China and a PhD in oncological sciences from the University of Utah. Her graduate work, under the mentorship of Drs. Bradley Cairns and Jingtao Guo, focused on human male reproductive biology. She specializes in single-cell genomics, germline stem cell biology, and testicular development. Currently serving as Scientific Manager at Paterna, Xichen leads a team dedicated to developing cutting-edge technologies for human in vitro spermatogenesis. In her spare time, she enjoys fitness, gardening, and spending time with her family.
Bingqian Guo, PhD
Bingqian (Bing) brings more than 10 years research experience in biology in both academia and industry to Paterna. Prior to joining Paterna she worked at the Contract Research Organization WuXi AppTec as a project leader on early-stage hit discovery projects, and established WuXi’s Fragment-Based Drug Discovery (FBDD) platform at the company’s Shanghai site. Bingqian earned a BS from the University of Science & Technology of China (USTC) and her PhD from Dartmouth College. She was then a postdoctoral fellow at Harvard Medical School and a Scientist II at the Huntsman Cancer Institute at the University of Utah. In her spare time, she enjoys traveling, painting, and hiking with her family.
Gabriela Cosma, PhD
Gabriela graduated with a BA in Biochemistry from the University of Pennsylvania. She then focused for three years on CD8+ T cell expansion and maturation during chronic infections as a research associate in a human immunology lab at the University of Pennsylvania School of Medicine, and then went on to earn her PhD in Immunology and Microbial Pathogenesis from Thomas Jefferson University. For her PhD work, she studied the effects of antigen presentation in pox virus infections on the development of CD8+ T cells. As a senior scientist at Paterna, she is excited to use her cell biology expertise for finding ways of expanding and differentiating spermatogonial stem cells in vitro. In her spare time, she enjoys visiting all the national parks within driving distance of Salt Lake City, playing chess, and spending time with her husband and two girls.
Zachary Olsen, MS
Graham Hickey, PhD
Joey Casalini, PhD
Senior Scientist
Joey holds a BA/BS from The Evergreen State College in Washington and PhD in biochemistry from the University of Utah. Prior to graduate school, Joey spent 6 years in biotech working on drug discovery and clinical device development at Presage Biosciences, a startup in Seattle, WA where his work directly contributed to the development and clinical advancement of anti-cancer drugs, the launching of multiple clinical trials with a novel device and 5 publications. Joey’s PhD work focused on novel macrophage-tumor cell interactions, demonstrating that pro-tumorigenic macrophages directly transfer dysfunctional mitochondria to breast cancer cells, which induce proliferative signaling cascades, promoting tumorigenesis in vitro and in vivo. As a Senior Scientist at Paterna, Joey is developing methodology to promote in vitro spermatogenesis. In his spare time Joey loves to cook, play music and thumb through his record collection.
Varshinee Devanand, MS
Varshinee graduated with a B.Tech in Biotechnology from PSG College of Technology, India. During her undergraduate work she focused on projects in molecular biology and genetic engineering. Varshinee has also worked with the CRISPR/Cas9 system to induce beneficial mutations in genes involved in Beta-thalassemia. She completed her MS in Biotechnology at Northeastern University, Boston. During her graduate studies she interned with ThermoFisher and worked on data collection from bioreactors with varying conditions to validate and compare different Raman spectroscopy-based instruments. As a Lab Associate at Paterna, she works under Bingqian to test and optimize various conditions to promote growth of spermatogonial stem cells in vitro. In her spare time, she enjoys practicing Indian Classical dance and reading books.
Board of Directors.
Cynthia Tsai
Independent Board Member
Cynthia Tsai has more than 30 years of experience in global biotechnology and medical technology. She spent 16 years on Wall Street as a Vice President with Merrill Lynch and Kidder Peabody (1982-1995). Since 2016, she has been the CEO of Tana Systems, a global software and IT company based in the U.S. and India, leading a team of 50 engineers in the U.S. and 500 engineers in India. She is also the Chief Executive Officer of Healthquest, a global biotechnology and medical technologies advisory firm. Past roles include CEO of HealthExpo and General Partner in MassTech Ventures, an equity fund focused on technology development at Massachusetts Institute of Technology. She currently serves on the Board of Selectors for the Jefferson Foundation Awards, the Prix Galien Foundation, Certus Critical Care Inc., Vita Nav TitinKM and Ethan Allen. She earned a B.A. in Psychology from the University of Missouri.
Deirdre Conway
Since 2012, Deirdre Conway has been a Partner at the Utah Fertility Center specializing in Reproductive Endocrinology and Infertility. Prior roles include Associate Reproductive Partners Medical Group at UCSD where she also served as a Clinical Instructor. Deirdre is a Penn State graduate with post graduate work at the NIH in Recombinant DNA Technology and Virology before attending MD studies at University of Pittsburgh School of Medicine. She completed her Internship and Residency in Obstetrics and Gynecology at NYU and a Fellowship in Reproductive Endocrinology and Infertility at UCLA’s David Geffen School of Medicine. She is widely published, a frequent conference speaker and has received numerous industry awards. Deirdre enjoys international travel, biking, running, yoga and is an alumna of the Burke Mountain Ski Racing Academy.
Tony Pellicer
Antonio Pellicer obtained his medical degree from the University of Valencia in 1980 and specialized in Obstetrics and Gynecology, with subspecialty training in Reproductive Medicine at the Yale School of Medicine (USA) and at the University of Mainz (Germany). In 1990, Tony founded the “Instituto Valenciano de Infertilidad” (“IVI”), expanding to numerous locations in Spain and internationally. He is also the President of the IVI Foundation for the Study of Reproduction and Director of the IVI Team. He has been a Professor of Obstetrics and Gynaecology since 1999 and Dean of the Valencia University Medical School, Spain, from 2006 to 2012. He was also Head of Service of Obstetrics and Gynaecology at La Fe University Hospital from 2009 to 2016, and since 2020 has held the position of CEO at IVIRMA Global. Tony is a member of the Executive Board of ESHRE (European Society of Human Reproduction and Embryology) and the International Federation of Fertility Societies, and is a member of the National Commission of Human Assisted Reproduction. He is extraordinarily well published, has been Co-Editor and Editor-in-Chief of the journal “Fertility & Sterility” since 2011 and is on the editorial boards of several scientific societies. Tony has also received many awards for his contributions to reproductive medicine.
Carlos Blanes
Carlos obtained his degree in industrial engineering in 2000 and his MBA in 2016 from Universitat Politècnica de València (UPV). From 2000-2006 he worked as a consultant for Deloitte, but since then has built his career as an executive with broad experience in management. Since 2020 Carlos has served as Deputy CEO at IVI-RMA. He joined IVI and has participated in its growth since 2006, being promoted to progressively larger roles over the last 15 years. In 2017, Carlos helped consummate IVI’s merger with RMANJ, with IVIRMA Global becoming the world leader in Reproductive Medicine with the largest global fertility network. He served as IVIRMA Global’s Chief of Staff from 2018 to 2020, when he was promoted to Deputy CEO.
Marc Entrecanales
Marc received his European Master in Management from ESCP Business School in 2002 and subsequently joined Deloitte as an auditor. After progressively larger and more senior roles at Bombardier, LVMH group, Bata Group, and Grupo Endeka, Marc joined IVI-RMA Global as CFO in 2019. Marc is a results-driven, business oriented, multicultural and multilingual senior CFO with over 15 years experience, having been named as one of the 100 best CFOs in Spain consecutively in 2016 and 2017. He brings to the table his expertise in value creation, financial and strategic planning, accounting and financial operations, complex tax and legal matters, audit, and staff management.
Francisco Jiménez
Francisco has a broad experience in broad in General Management, Strategy, Transformation, Corporate Finance and M&A, working for companies owned by PE funds and / or institutional investors, as well as listed companies.
He started his career as consultant in PwC, and worked in different companies across industries – such as Uralita, Levantina and Planasa – mainly as CFSO, until he joined Igenomix, in early 2020, where he served as CFO & Strategy Director. He actively participated in the successful exit of EQT, in summer 2022, when the company was acquired by Vitrolife, where he joined the Executive Team of the combined company as SVP Strategy and Corporate Development. Since summer 2022, he has been working in different roles of the new IVF-clinics group formed by KKR. He currently leads the integration of acquisitions as well as the transformation initiatives.
Francisco education includes an MSc in Industrial Engineering double degree from Universidad Politecnica de Valencia (UPV) and Cranfield University, an MBA from Instituto de Empresa, and a Senior Executive Programme from London Business School.
Advisors.
Pete Thurlow, MBA
Pete received his BS from the U.S. Merchant Marine Academy in 1988, his MBA from Pace University in 1992 and his JD from Brooklyn Law School in 1996. He is an experienced patent attorney, focusing on protecting intellectual property rights with a practice that involves the full spectrum of patent law. Because of his extensive experience working on matters at the USPTO, Pete served on the USPTO’s Patent Public Advisory Committee (PPAC) from 2012-2018, having been appointed by the U.S. Secretary of Commerce. Pete spent a decade in the U.S. Navy Reserve and has coupled his military background with his legal experience in his advisory work with the Defense Advanced Research Projects Agency (DARPA). He was the President of the New York Intellectual Property Law Association (NYIPLA) in 2018-2019, the primary intellectual property law association in New York.
Don Conrad, PhD
Don Conrad, PhD, is Associate Professor and Chief of Genetics of the Oregon National Primate Research Center at Oregon Health Sciences University, with over 15 years experience in developing statistical and experimental methods for genome analysis. Don received his AB in Biochemistry and Molecular Biology from Dartmouth in 1999 and his PhD in Human Genetics from the University of Chicago in 2007. He completed his postdoctoral training at the Wellcome Trust Sanger Institute in the UK in 2010. Don then joined the faculty at Washington University in St. Louis where he ran a research group in the Department of Genetics, and was subsequently recruited as Chief of Genetics at the newly established Division of Genetics at the Primate Center at OHSU. Don’s lab has a special interest in testis biology and has investigated genes in testicular germ cells, purifying testicular cell populations, mapping functional elements of germ cell genomics, characterized testis pathology and investigated the role of the immune system in regulation of spermatogenesis.
Ki Aston, PhD
Ki Aston received his PhD from Utah State University, with his dissertation focusing on factors associated with somatic cell nuclear transfer efficiency and nuclear reprogramming. He was involved in bovine nuclear transfer and was part of the first group to successfully clone an equine species. Upon completion of his graduate training, Ki joined the Andrology and IVF lab at the University of Utah as a postdoctoral fellow, and in 2011 he joined the faculty. Ki is currently an Associate Professor at the University of Utah School of Medicine. In addition to his clinical work as the Andrology and IVF Lab Director, he maintains an active research program focused on identifying genetic and epigenetic factors associated with male infertility, and is co-founder of two international consortia to study the genetics of male infertility, The Genetics of Male Infertility Initiative (GEMINI) and the International Male Infertility Consortium (IMIGC). In his free time, Ki loves spending time outdoors with his wife and four children pursuing activities including mountain biking, fly fishing, backpacking and skiing.
Doug Carrell, PhD
Doug received his BS in Zoology and MS in Cellular & Developmental Biology from Brigham Young University, and his PhD in Physiology from the University of Utah in 1996, where he subsequently joined the faculty. Doug has been a Professor in the departments of Surgery (Urology), Human Genetics, and Obstetrics & Gynecology, and has served as the Director and Principal Investigator of the University of Utah In Vitro Fertilization and Andrology Laboratories. He currently serves as Andrology Lab Director of the Center for Reproductive Medicine & Advanced Reproductive Technologies in Minnesota. Doug is widely published on in vitro fertilization and the genetic aspects of infertility. He also serves as Co-Editor-in-Chief of the journal Andrology and sits on the editorial board of numerous other journals. As an entrepreneur, Doug was Founder and CEO of Specialized Biotechnology Services, and is a Cofounder of Episona.
David Bearss, PhD
David is an experienced entrepreneur and drug developer, having over 20 years of drug discovery and development experience that spans the last 20 years. He has discovered 15 compounds that have moved forward in clinical development. David received his BS in Human Biology in 1994 from Brigham Young University and his PhD in Cell & Molecular Biology from the University of Texas at San Antonio in 1999. David joined the faculty of the University of Arizona in 2000 and subsequently went on to numerous founding, executive, and board roles at Montigen Pharmaceuticals, Salarius Pharmaceuticals, Tetragene, Wasatch Scientific, Tolero Pharmaceuticals, Xenter, BioLexis Therapeutics, and Halia Therapeutics, among others. David was the founder and CEO of Tolero Pharmaceuticals, which he led through its acquisition by Sumitomo DaiNippon Pharma in 2017. He stayed on after the acquisition as CEO of Tolero and as Global head of Research and CSO of SDP Oncology. David is also faculty at the University of Utah, Co-Director of the Center for Investigational Therapeutics at the Huntsman Cancer Institute, and Senior Managing Director of the U2TAH Therapeutics Accelerator. He has published over 80 manuscripts and book chapters, has over 50 patents, and has won numerous awards for his achievements.
Amy Divaraniya, PhD
Equal Employment Opportunity:
Paterna Biosciences is an Equal Employment Opportunity (EEO) employer committed to diversity and inclusion in the workplace. Every qualified applicant will receive consideration for employment without regard to race, color, religion, sex, gender identity or expression, national origin, sexual orientation, genetic information, disability, age, ancestry, military service, protected veteran status, or other groups as protected by law.
Overcoming male infertility.
Our moral and ethical statement: The founders and leadership of Paterna Biosciences recognize that work with stem cells is considered controversial by some. We can restore fertility using the patient’s own stem cells.
Our position is that we can solve genetic disorders that cause male infertility and beyond. That is our sole focus. We completely reject and will not pursue this work to enable modifications of heritable social traits. We view that as immoral and will have no part in it.
Disclaimer
THIS PRESENTATION IS FOR DISCUSSION AND GENERAL INFORMATIONAL PURPOSES ONLY. IT TAKES NO ACCOUNT OF ANY SPECIFIC INVESTMENT OBJECTIVE, FINANCIAL SITUATION, OR SUITABILITY FOR THE PARTICULAR NEED OF ANY SPECIFIC PERSON WHO MAY RECEIVE THIS PRESENTATION, AND SHOULD NOT BE TAKEN AS ADVICE ON THE MERITS OF ANY INVESTMENT DECISION. THE VIEWS EXPRESSED HEREIN REPRESENT THE OPINIONS OF Paterna. any
financial projections included in the INFORMATION have been compiled by paterna and are based on assumptions supplied by paterna which have not been verified by an outside accountants. therefore, any financial projections are limited to presenting in the form of forecast information the assumptions of paterna and do not include any evaluation of the support for the assumptions underlying the forecast. the financial projections are based upon information available to paterna as of the date of the particular COMPILATION, are subject to material uncertainties, and should not be viewed as a prediction or an assurance of ACTUAL FUTURE performance; hence, no investment decision should be made based solely on any projections included in the information. any financial projections contained herein will depend upon future events, INCLUDING a wide variety of significant business, economic and competitive risks, many of which will be beyond Paterna’s control and accordingly, no assurance can be given that paterna’s assumptions will prove true, that its projected results will be achieved, or that variations between the projections and actual future results will not be material.
THIS MATERIAL DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITies DESCRIBED HEREIN IN ANY JURISDICTION TO OR FROM ANY PERSON, NOR DOES IT CONSTITUTE FINANCIAL PROMOTION, INVESTMENT ADVICE OR AN INDUCEMENT OR AN INVITATION TO PARTICIPATE IN ANY PRODUCT, OFFERING OR INVESTMENT. THIS MATERIAL IS INFORMATIONAL ONLY AND SHOULD NOT BE USED AS THE BASIS FOR ANY INVESTMENT DECISION, NOR SHOULD IT BE RELIED UPON FOR LEGAL, ACCOUNTING OR TAX ADVICE OR INVESTMENT RECOMMENDATIONS OR FOR ANY OTHER PURPOSE. NO REPRESENTATION OR WARRANTY IS MADE THAT PATERNA’s INVESTMENT PROCESSES OR INVESTMENT OBJECTIVES WILL OR ARE LIKELY TO BE ACHIEVED OR SUCCESSFUL OR THAT PATERNA’s INVESTMENT WILL MAKE ANY PROFIT OR WILL NOT SUSTAIN LOSSES. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS.
NO AGREEMENT, COMMITMENT OR UNDERSTANDING EXISTS OR SHALL BE DEEMED TO EXIST BETWEEN OR AMONG PATERNA AND ANY OTHER PARTY OR PARTIES BY VIRTUE OF PATERNA FURNISHING THIS PRESENTATION OR ANY PARTY RECEIVING THIS PRESENTATION. PATERNA HAS NOT SOUGHT OR OBTAINED CONSENT FROM ANY THIRD PARTY TO USE ANY STATEMENTS OR INFORMATION INDICATED HEREIN AS HAVING BEEN OBTAINED OR DERIVED FROM STATEMENTS MADE OR PUBLISHED BY THIRD PARTIES. ANY SUCH STATEMENTS OR INFORMATION SHOULD NOT BE VIEWED AS INDICATING THE SUPPORT OF SUCH THIRD PARTY FOR THE VIEWS EXPRESSED HEREIN. NO WARRANTY IS MADE THAT DATA OR INFORMATION, WHETHER DERIVED OR OBTAINED FROM FILINGS MADE WITH THE UNITED STATES SECURITIES AND EXCHANGE COMMISSION OR FROM ANY THIRD PARTY, ARE ACCURATE OR COMPLETE. EXCEPT FOR THE HISTORICAL INFORMATION CONTAINED HEREIN, THE MATTERS ADDRESSED IN THIS PRESENTATION ARE FORWARD-LOOKING STATEMENTS, WHICH CAN BE IDENTIFIED by the use of forward-looking terminology such as “may,” “will,” “seek,” “should,” “Expect,” “Anticipate,” “project,” “projection,” “pro-forma,” “attempt,” “target,” “develop,” “estimate,” “intend,” “Working to,” “working toward,” “continue,” or “believe” or the negatives thereof or other VARIATIONS thereon or comparable terminology. YOU SHOULD BE AWARE THAT PROJECTIONS AND FORWARD LOOKING STATEMENTS INVOLVE CERTAIN RISKS AND ARE INHERENTLY UNCERTAIN AND ACTUAL RESULTS MAY DIFFER FROM THE PROJECTIONS AND OTHER FORWARD LOOKING STATEMENTS CONTAINED HEREIN DUE TO REASONS THAT MAY OR MAY NOT BE FORESEEABLE. NO REPRESENTATION OR WARRANTY IS MADE AS TO THE ACCURACY OR REASONABLENESS OF THE ASSUMPTIONS UNDERLYING THE PROJECTIONS AND OTHER FORWARD LOOKING STATEMENTS CONTAINED HEREIN.
ALL AMOUNTS, MARKET VALUE INFORMATION AND ESTIMATES INCLUDED IN THIS MATERIAL HAVE BEEN OBTAINED FROM OUTSIDE SOURCES THAT PATERNA BELIEVES TO BE RELIABLE OR REPRESENT THE REASONABLE JUDGMENT OF PATERNA AS OF THE DATE OF THIS MATERIAL. NO REPRESENTATION, WARRANTY OR UNDERTAKING, EXPRESS OR IMPLIED, IS GIVEN AS TO THE ACCURACY OR COMPLETENESS OF THE INFORMATION OR VIEWS CONTAINED HEREIN. PROJECTIONS, MARKET OUTLOOKS, ASSUMPTIONS OR ESTIMATES IN THIS MATERIAL ARE FORWARD-LOOKING STATEMENTS, ARE BASED UPON CERTAIN ASSUMPTIONS, AND ARE SUBJECT TO A VARIETY OF RISKS AND CHANGES, INCLUDING RISKS AND CHANGES AFFECTING INDUSTRIES GENERALLY AND THE COMPANY SPECIFICALLY.
PATERNA RESERVES THE RIGHT TO CHANGE OR MODIFY ANY OF ITS OPINIONS EXPRESSED HEREIN AT ANY TIME AS IT DEEMS APPROPRIATE. PATERNA DISCLAIMS ANY OBLIGATION TO UPDATE THE INFORMATION OR VIEWS CONTAINED HEREIN.